Clinical trial · Observational
Ribomustin in the First Line Therapy of Chronic Lymphocytic Leukemia
Observational Program for Evaluation of Ribomustin Use in the First Line Therapy of Chronic Lymphocytic Leukemia
NCT02110394CI-TRIAL-00022860NORMAcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective multicenter observational non-interventional study to assess routine clinical practice of Bendamustine use in the first line therapy of chronic lymphocytic leukemia
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| bendamustine | Other | — | UNRESOLVED |
| rituximab | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- bendamustine and rituximab
- interventionNames
- Other: bendamustine
- Other: rituximab
Primary outcomes (1)
- measure
- Overall response rate
- timeFrame
- Within 60-90 days after end of treatment
Secondary outcomes (7)
- measure
- Adverse drug reactions
- timeFrame
- At all post-treatment visits (up to 30 days after end of treatment)
- measure
- Treatment Failure (TF)
- timeFrame
- Within 60-90 days after end of treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with chronic lymphocytic leukemia (CLL) with current or planned first line therapy with Ribomustin * Informed Consent Form for personal data handling signed by the program participant Exclusion Criteria: * Any prior chemotherapy and/or radiotherapy and/or immunotherapy and/or any investigational agent for treatment of CLL * Currently participating in any clinical trial, and/or has taken an investigational drug within 28 days prior to enrollment * Contraindications for Ribomustin usage in accordance with product label
References
Publications (0)
Data not yet available
No reference posted for this study.